Published in World J Surg on June 01, 2005
Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg (2009) 1.84
Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg (2008) 1.65
Surgical outcomes of intrahepatic cholangiocarcinoma. Surg Today (2011) 1.29
Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) (2015) 1.08
Detection of distant metastasis to skeletal muscle by 18F-FDG-PET in a case of intrahepatic cholangiocarcinoma. Korean J Hepatol (2010) 1.05
Surgical outcomes of the mass-forming plus periductal infiltrating types of intrahepatic cholangiocarcinoma: a comparative study with the typical mass-forming type of intrahepatic cholangiocarcinoma. World J Surg (2007) 1.05
Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma. World J Gastroenterol (2009) 1.00
Hepatitis B virus infection: a favorable prognostic factor for intrahepatic cholangiocarcinoma after resection. World J Gastroenterol (2011) 0.97
Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J Surg (2007) 0.96
Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am (2014) 0.95
Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database. HPB (Oxford) (2011) 0.91
Routine lymph node dissection may be not suitable for all intrahepatic cholangiocarcinoma patients: results of a monocentric series. World J Gastroenterol (2013) 0.91
Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol (2007) 0.89
Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford) (2012) 0.88
Staging of peripheral-type intrahepatic cholangiocarcinoma: appraisal of the new TNM classification and its modifications. World J Surg (2011) 0.88
Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 0.87
Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management. Gastroenterol Res Pract (2015) 0.87
Clinical impact of lymph node dissection in surgery for peripheral-type intrahepatic cholangiocarcinoma. Surg Today (2011) 0.86
Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis. Surg Today (2014) 0.86
Factors affecting survival after resection of intrahepatic cholangiocarcinoma. Surg Today (2014) 0.85
Benefit of radiotherapy for 90 patients with resected intrahepatic cholangiocarcinoma and concurrent lymph node metastases. J Cancer Res Clin Oncol (2010) 0.83
Clinical parameters predicting survival duration after hepatectomy for intrahepatic cholangiocarcinoma. Can J Gastroenterol (2011) 0.82
Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling. BMC Clin Pathol (2014) 0.81
Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma. World J Gastroenterol (2015) 0.80
The value of systematic lymph node dissection for intrahepatic cholangiocarcinoma from the viewpoint of liver lymphatics. J Gastroenterol (2015) 0.80
The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma: A single-center experience. Medicine (Baltimore) (2016) 0.80
Prediction of the postoperative prognosis of intrahepatic cholangiocarcinoma (ICC): importance of preoperatively- determined anatomic invasion level and number of tumors. Dig Dis Sci (2014) 0.79
A simple and effective prognostic staging system based on clinicopathologic features of intrahepatic cholangiocarcinoma. Am J Cancer Res (2015) 0.77
Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies. Clin Med Insights Oncol (2016) 0.77
Prediction of the lymph node status in patients with intrahepatic cholangiocarcinoma: analysis of 320 surgical cases. Front Oncol (2011) 0.76
Impact of lymph node status in patients with intrahepatic cholangiocarcinoma treated by major hepatectomy: a review of the National Cancer Database. HPB (Oxford) (2016) 0.76
Influence of surgical margins on overall survival after resection of intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore) (2016) 0.75
Diagnosis and surgical treatment of intrahepatic hepatolithiasis combined with cholangiocarcinoma. World J Surg (2014) 0.75
Locally Advanced Intrahepatic Cholangiocarcinoma: Complete Pathologic Response to Neoadjuvant Chemotherapy Followed by Left Hepatic Trisectionectomy and Caudate Lobectomy. Dig Dis Sci (2015) 0.75
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer (1983) 3.94
Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol (1986) 2.80
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg (2001) 2.57
Outcomes after curative resections of cholangiocarcinoma. Arch Surg (1993) 2.26
Report of the 15th follow-up survey of primary liver cancer. Hepatol Res (2004) 1.78
Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg (2002) 1.75
Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg (1997) 1.36
Surgical management of intrahepatic cholangiocarcinoma: a 31-year experience. J Hepatobiliary Pancreat Surg (1998) 1.24
Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg (2001) 1.20
Clinicopathological features and outcome of hepatic resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg (1999) 1.17
Intrahepatic cholangiocarcinoma. World J Surg (1997) 1.11
Analysis of the relationships between clinicopathologic factors and survival time in intrahepatic cholangiocarcinoma. Am J Surg (2002) 1.05
Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg (2001) 0.99
Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg (2002) 0.98
Involvement of three or more lymph nodes predicts poor prognosis in submucosal gastric carcinoma. Gastric Cancer (2001) 0.97
Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. Clin Cancer Res (2000) 0.95
Lymphatic spreading pattern of intrahepatic cholangiocarcinoma. Surgery (2001) 0.95
Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg (1999) 0.90
Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes. Hepatogastroenterology (2002) 0.84
A long-term survivor of intrahepatic cholangiocarcinoma with lymph node metastasis: a case report. Jpn J Clin Oncol (2002) 0.81
Magnetic resonance imaging for preoperative evaluation of breast cancer: a comparative study with mammography and ultrasonography. J Am Coll Surg (2004) 2.57
Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys (2003) 2.00
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res (2006) 1.90
Identification of novel serum biomarkers of hepatocellular carcinoma using glycomic analysis. Hepatology (2013) 1.76
Evidence for hyperacute rejection of human liver grafts: The case of the canary kidneys. Clin Transplant (1989) 1.74
Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer (2005) 1.73
Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol (2002) 1.72
EFFECT OF CYCLOSPORIN ON HEPATIC REGENERATION. Surg Forum (1986) 1.59
Transient portacaval shunt for a small-for-size graft in living donor liver transplantation. Liver Transpl (2007) 1.57
Induction of donor-specific tolerance by adenovirus-mediated CD40Ig gene therapy in rat liver transplantation. Transplantation (2002) 1.57
Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann N Y Acad Sci (2003) 1.56
Risk factors for portal vein complications in pediatric living donor liver transplantation. Clin Transplant (2010) 1.39
Overexpression of cortactin is involved in motility and metastasis of hepatocellular carcinoma. J Hepatol (2004) 1.37
Compensatory recovery of liver mass by Akt-mediated hepatocellular hypertrophy in liver-specific STAT3-deficient mice. J Hepatol (2005) 1.31
Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol (2009) 1.30
She4p/Dim1p interacts with the motor domain of unconventional myosins in the budding yeast, Saccharomyces cerevisiae. Mol Biol Cell (2003) 1.29
Perioperative management of hepatic resection toward zero mortality and morbidity: analysis of 793 consecutive cases in a single institution. J Am Coll Surg (2010) 1.28
The survival pathways phosphatidylinositol-3 kinase (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt modulate liver regeneration through hepatocyte size rather than proliferation. Hepatology (2009) 1.26
Control of intraoperative bleeding during liver resection: analysis of a questionnaire sent to 231 Japanese hospitals. Surg Today (2002) 1.19
Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res (2005) 1.19
The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther (2008) 1.15
The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol (2009) 1.13
Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.11
Real-time monitoring of a digestive tract marker to reduce adverse effects of moving organs at risk (OAR) in radiotherapy for thoracic and abdominal tumors. Int J Radiat Oncol Biol Phys (2005) 1.10
Preoperative evaluation of hepatic vasculature by three-dimensional computed tomography in patients undergoing hepatectomy. World J Surg (2006) 1.10
Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology (2008) 1.10
Postnatal management for prenatally diagnosed choledochal cysts. J Pediatr Surg (2004) 1.09
UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene (2005) 1.08
Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res (2002) 1.07
Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. Pancreas (2011) 1.06
Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res (2004) 1.05
Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology (2004) 1.04
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Alveolar echinococcosis: MR findings in the liver. Radiology (2003) 1.04
BlotGlycoABCTM, an integrated glycoblotting technique for rapid and large scale clinical glycomics. Mol Cell Proteomics (2007) 1.03
A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation (2007) 1.03
N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer (2007) 1.03
Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep (2010) 1.03
Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl (2011) 1.02
Physical interaction of p73 with c-Myc and MM1, a c-Myc-binding protein, and modulation of the p73 function. J Biol Chem (2002) 1.01
Three-dimensional computed tomography scan analysis of hepatic vasculatures in the donor liver for living donor liver transplantation. Liver Transpl (2010) 1.01
A long-term survival case of adult undifferentiated embryonal sarcoma of liver. World J Surg Oncol (2012) 1.00
Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. World J Surg Oncol (2013) 0.99
Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep (2010) 0.99
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci (2003) 0.98
C-ERC/mesothelin provokes lymphatic invasion of colorectal adenocarcinoma. J Gastroenterol (2013) 0.97
A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. J Crohns Colitis (2011) 0.97
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol (2012) 0.96
Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001). Int J Clin Oncol (2014) 0.96
Functional characteristics of lymphocytes propagated from a human multivisceral allograft. Clin Transplant (1990) 0.94
Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol (2011) 0.94
TRIM40 promotes neddylation of IKKγ and is downregulated in gastrointestinal cancers. Carcinogenesis (2011) 0.94
AFP mRNA detected in bone marrow by real-time quantitative RT-PCR analysis predicts survival and recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg (2006) 0.93